ORGALUTRAN Solution for injection Ref.[9568] Active ingredients: Ganirelix

Source: European Medicines Agency (EU)  Revision Year: 2020  Publisher: Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands

Product name and form

Orgalutran 0.25 mg/0.5 mL solution for injection.

Pharmaceutical Form

Solution for injection.

Clear and colourless aqueous solution.

Qualitative and quantitative composition

Each pre-filled syringe contains 0.25 mg of ganirelix in 0.5 mL aqueous solution. The active substance ganirelix (INN) is a synthetic decapeptide with high antagonistic activity to the naturally occurring gonadotrophin releasing hormone (GnRH). The amino acids at positions 1, 2, 3, 6, 8 and 10 of the natural GnRH decapeptide have been substituted resulting in N-Ac-D-Nal(2)1, D-pClPhe2, D-Pal(3)3, D-hArg(Et2)6, L-hArg(Et2)8, D-Ala10]-GnRH with a molecular weight of 1570.4.

Excipient with known effect: This medicinal product contains less than 1 mmol sodium (23 mg) per injection, that is to say essentially ‘sodium-free’.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Ganirelix

Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitive binding to the GnRH receptors in the pituitary gland. As a result a rapid, profound, reversible suppression of endogenous gonadotrophins occurs, without initial stimulation as induced by GnRH agonists.

List of Excipients

Acetic acid
Mannitol
Water for injections

The pH may have been adjusted with sodium hydroxide and acetic acid.

Pack sizes and marketing

Disposable pre-filled syringes (siliconised type I glass), containing 0.5 mL of sterile, ready for use, aqueous solution closed with a rubber piston that does not contain latex. Each pre-filled syringe is affixed with a needle closed by a needle cover of dry natural rubber/latex which comes into contact with the needle. (See section 4.4.)

Supplied in cartons containing 1 or 5 pre-filled syringes.

Not all pack sizes may be marketed.

Marketing authorization holder

Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands

Marketing authorization dates and numbers

EU/1/00/130/001, 1 pre-filled syringe
EU/1/00/130/002, 5 pre-filled syringes

Date of first authorisation: 17 May 2000
Date of last renewal: 10 May 2010

Drugs

Drug Countries
ORGALUTRAN Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.